Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression. The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer. This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field. Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice-making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research. INDICE: Tentative TOC: Introduction: Chapter 1.0 Development and Structure of the Lymphoid System embryologic development gross anatomy of the human immune system lymphatic endothelial cells, heterogeneity of, and lymph node microscopic structure lymph node function; afferent lymph cellular components role of the gut microbiome in immune system development specific functions related to the spread of cancer cancer-induced lymphangiogeneis; sentinel LNs Chapter 2.0 The Chemistry, Structure, and Function of Immunoglobulins immunoglobulin isotypes the structure of immunoglobulins the genetics of immunoglobulin diversity antibody-dependent cellular cytotoxicity heavy-chain C domain and role of glycosylation the development of humanized monoclonals Chapter 3.0 The Role of the Complement System in Cancer complement system activation pathways (classical, alternative and lectin) the role of complement activation in cancer progression complement regulatory proteins (CRPs) and cancer the role of compliment activation in the tumor microenvironment enhances tumor growth complement-dependent cytotoxicity in immune therapy of cancer formation of the membrane attack complex (MAC) potential application of anti-complement cancer therapies (C3aR/C5aR/IL-10 pathway) Chapter 4.0 Cancer as Non-Self 4.1 primary generator of tumor-specific transplantation type antigens 4.2 character of non-self, tumor associated antigens 4.3 immune surveillance - innate immunity 4.4 distinguishing between self and non-self 4.5 toll-like receptors (TLRs); soluble bioactive proteins such as cytokines and C' proteins 4.6 NK cells Chapter 5.0 The Adaptive Immune Response in Cancer the diversity of active tumor antigen receptors target specificity without limits in cancer-receptor variability tumor antigen presentation; dendritic cells immune response stimulation against the cancer Cytotoxic T-cells and T-regulatory cells B-cells and antibodies Chapter 6.0 The Science of Innate Immunity 6.1 critical regulator of human inflammatory disease 6.2 anatomic and physiologic barriers to pathogens - cancer causing viruses 6.3 centrally a limited number of critical receptors 6.4 the character of the inflammatory response 6.5 lack of ability to form memory 6.5 role in activating subsequent adaptive immune response Chapter 7.0 Immune Surveillance 7.1 history of concept (Ilya Mechnikov 1908 Nobel Prize) 7.2 evidence for immune surveillance today 7.3 cancer in the immunocompromised host Chapter 8.0 Cancer - Avoiding Immune Detection 8.1 cancer and the presence of immune resistance 8.2 concept for the development of tumor cell tolerance Chapter 9.0 Active Immunization Against Cancer and Cell-based Therapies 9.1 infusing in-vitro expanded Tumor Infiltrating Lymphocytes (TILs) 9.2 infusing dendritic cells pre-loaded with tumor specific oligopeptide antigens 9.3 B7 co-activating receptor 9.4 vaccines Chapter 10.0 The Three Major Clinical Components of Cancer Immunotherapy (modulating cell-mediated immune mechanisms) 10.1 the role of and application of check point blockade 10.2 the role and application of cell-based therapies including CAR-T cell therapies 10.3 antibodies (and vaccines); monoclonal antibodies and novel application of bi- or tri-specifics Chapter 11.0 The Clinical Application of Immunotherapeutics 11.1 in melanoma cancer 11.2 in breast cancer 11.3 in pancreatic cancer 11.4 in colon and rectum cancer 11.5 in prostate cancer 11.6 in leukemias and hematologic malignancies 11.7 in other malignancies Chapter 12.0 Cancer Immunotherapy in the Presence of COVID-19 12.1 immune response to coronavirus-2 infection 12.2 CD8+ T cell depression during chronic viral infection and cancer 12.3 checkpoint inhibitors in cancer patients with coronavirus infection 12.4 coronavirus depletion of CD4+ T cells
- ISBN: 978-0-323-87763-3
- Editorial: Elsevier
- Encuadernacion: Cartoné
- Páginas: 336
- Fecha Publicación: 09/06/2023
- Nº Volúmenes: 1
- Idioma: Inglés